DFTX
The table below shows Definium Therapeutics, Inc.'s balance sheet line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & equivalents | $257.84M | $273.74M | $99.70M | $142.14M | $133.54M |
| Short-term investments | $153.76M | - | - | - | - |
| Receivables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Total current assets | $419.32M | $281.62M | $103.87M | $146.06M | $137.22M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Property, plant & equipment | - | - | - | - | - |
| Goodwill | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M |
| Total assets | $440.10M | $302.15M | $124.54M | $169.99M | $164.00M |
| Accounts payable | $5.35M | $2.01M | $4.14M | $2.11M | $4.18M |
| Total current liabilities | $66.70M | $38.85M | $32.25M | $17.89M | $10.41M |
| Long-term debt | $40.58M | $21.85M | $14.13M | - | - |
| Total liabilities | $107.77M | $60.70M | $46.41M | $19.08M | $12.34M |
| Retained earnings | -$582.67M | -$398.88M | -$290.20M | -$194.47M | -$137.67M |
| Total equity | $332.33M | $241.45M | $78.13M | $150.92M | $151.66M |